Suppression of high M r tropomyosins (TMs) is a common feature of transformed cells. Previous work from this laboratory has demonstrated that the isoform 1 of TM, TM1, acts as an anti-oncogene in rastransformed murine ®broblasts. In this study, we have investigated whether TM1 is a ras-speci®c suppressor, or a general suppressor protein of the cellular transformation. V-src transformed ®broblasts, which express decreased TM1, were transduced with a full-length cDNA to overexpress TM1. Both the control and the transduced cells expressed v-src kinase at comparable levels. TM1 expressing (src-T1) cells grew at a lower rate in monolayer, exhibited well spread,¯at morphology than the control cells. Enhanced expression of TM1 resulted in improved micro®lamental architecture. More signi®cantly, src-T1 cells completely failed to grow under anchorage independent conditions. These data demonstrate that TM1 is as an anti-oncogene of functionally diverse oncogenes, and it is a class II tumor suppressor protein.
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Keywords: tropomyosin; src; oncogenes; transformation; tumor suppression; cytoskeleton The cytoskeleton of mammalian cells, in addition to providing shape and support, is implicated in a variety of important physiological processes (Button et al., 1995) . Changes in the expression of a number of micro®lament-associated proteins during neoplastic transformation have been well documented (Button et al., 1995; Jammey and Chaponnier, 1995) . For example, the expression of gelsolin (Vandekerckhove et al., 1990) , vinculin (FernaÂ ndez et al., 1992) , a-actinin (GluÈ ck et al., 1993) and tropomyosins (Leonardi et al., 1982; Cooper et al., 1985; Lin et al., 1985; Matsumura et al., 1983) , which bind to and/or modulate the polymerization status of actin, is reported to be down regulated as the cells acquire malignant phenotype.
Tropomyosins (TMs) are a family of important actin binding proteins which stabilize actin in the micro®laments (Lin et al., 1997; Pittenger et al., 1994) . TMs are a-helical, rod-shaped proteins, classi®ed into high and low M r isoforms, consisting of 284 and 247 amino acids (aa), respectively. Four genes, by alternative splicing, code for multiple isoforms of TMs in a highly tissue speci®c manner (Pittenger et al., 1994) . For example, in ®broblasts, a total of ®ve dierent TMs are expressed: TM1 (M r , 41 kDa), TM2 (M r , 36 kDa) and TM3 (M r , 35 kDa), each with 284 aa, are referred to as high M r isoforms. TM4 and TM5 (each with M r of 32 kDa) contain 247 aa and are described as low M r isoforms (Cooper et al., 1985; Prasad et al., 1993) . The function of TMs in muscle cells, in conjunction with the troponins, as the components of actin-myosin contractile apparatus, is well-de®ned (Lin et al., 1997; Pittenger et al., 1994) . However, in non-muscle cells the function(s) of TMs, given the tissue speci®c expression of multiple isoforms of TMs, coupled with the absence of troponin complex, is largely unknown; also, it is unclear whether each of the isoforms performs any unique cell type speci®c functions. Recent ®ndings from several laboratories suggest that the individual TMs may perform speci®c, as well as overlapping functions in the cell (reviewed in Lin et al., 1997; Pittenger et al., 1994) .
The goal of our research is to understand the role of TMs in cell physiology and to elucidate the involvement of TMs in neoplastic transformation of cells (Cooper et al., 1985 (Cooper et al., , 1987 Bhattacharya et al., 1988 Bhattacharya et al., , 1990 . Our previous work has established that TM1 suppression is a common biochemical change in the cells undergoing neoplastic transformation, by various oncogenic modalities (Cooper et al., 1985) . For example, in murine ®broblasts transformed with v-kiras (DT cells) the expression of TM1 is suppressed to 50% levels found in normal NIH3T3 cells. Similar changes in TM1 expression were noted in cells transformed with other biochemically unrelated oncogenes, viz., ras, mos, fes, fms and v-src, and other transforming agents. In a number of human breast (Bhattacharya et al., 1990 ) and prostate carcinoma cell lines (Wang et al., 1996; Prasad unpublished data) , TM1 expression is consistently abolished. Thus, during the multistep oncogenesis the diverse primary transforming agents appear to commonly suppress TM and ultimately lead to the neoplastic growth. Therefore, TM suppression may be a key event in tumorigenesis. Suppression of TMs results in the formation of deranged actin micro®laments, which in turn contributes to the neoplastic phenotype.
In support of this hypothesis, we have recently demonstrated that tropomyosin-1 (TM1) is an antioncogene (Braverman et al., 1996) . Restoration of TM1 expression abolishes the transformed phenotype induced by v-ki-ras oncogene (Prasad et al., 1993) . Furthermore, enhanced expression of a closely related isoform, tropomyosin 2 (TM2), does not in¯uence the transformed phenotype of DT cells (Braverman et al., 1996) . Since several oncogenic modalities suppress TM1 expression, it remained to establish whether TM1 is a ras-speci®c suppressor protein, or whether it can inhibit the neoplastic potential of other oncogenes as well.
In this communication, we have examined the antioncogenic eects of TM1 using a well-characterized retroviral oncogene, v-src. V-SRC tyrosine kinase is one of the best-studied oncoproteins (Erpel and Courtneidge, 1995; Parsons and Parsons, 1997; Thomas and Brugge, 1997; Superti-Furga, 1995) , and it is biochemically distinct from Ras, which is a GTPase. Moreover, SRC is closely associated with the reorganization of the cytoskeleton (Chang et al., 1995; Shriver and Rohrschneider, 1981) and its targets include many cytoskeletal proteins (Flynn et al., 1993; Nigg et al., 1986) . Oncogenic forms of src have been reported to associate preferentially with the cytoskeletal compartment (Okamura and Resh, 1994; Kellie et al., 1993) . Similarly, activated pp60 c-src also redistributes to the cytoskeletal compartment (Clark and Brugge, 1993; Weerlink and Rijksen, 1995) : the cytoskeletal association is presumed to facilitate interaction with the putative substrates. We have restored the expression of TM1 in v-src-transformed murine ®broblasts and evaluated its eects on the transformed phenotype.
The v-src-transformed NIH3T3 cells (3T3/src cells) express a reduced level (50%) of TM1 protein and its cognate mRNA compared to NIH3T3 cells (Cooper et al., 1985) . The 3T3/src cells readily form colonies in agar, in anchorage independent fashion, as well as manifest morphological features concomitant with the transformed phenotype. In order to test whether the anti-oncogenic eects of TM1 are speci®c to ras oncogene (Prasad et al., 1993) , or whether the transformed phenotype induced by other functionally oncogenes could also be suppressed by TM1, we have restored the expression of TM1 in v-src transformed NIH3T3 cells.
The TMe1 cDNA that encodes the TM1 protein was isolated from a human colon carcinoma cell line and subcloned into pBNC retroviral vector (Prasad et al., 1991; . The recombinant vector was used to transfect the C 2 packaging cell line and the infectious supernatants were used to infect the 3T3/src cells followed by selection with G418. Drug resistant cells were cloned and expanded into cell lines designated as src/T1 cells. The individual cell lines were distinguished as T1-1 through T1-9.
TM1 expression
In normal NIH3T3 cells, TM1 is expressed from a 1.1 kb mRNA whose expression is down regulated to 50% levels in 3T3/src cells. This decrease in mRNA expression is re¯ected in a corresponding reduction in the TM1 synthesis in src-transformed ®broblasts.
The transduced TMe1 cDNA is expressed as a 2.0 kb mRNA, distinct from the endogenous murine TM1 (1.1 kb) mRNA. To detect the expression of the transduced sequence, Northern blot analysis was performed using an oligonucleotide probe, designated as 5'ORF/probe. This probe consists of the complementary sequence of the ®rst 30 nucleotides of the coding region of TMe1 cDNA. This probe recognizes both the endogenous murine TM1 message, as well as the transduced sequence. As evident from Figure 1a , in three independent cell lines that were generated by transduction of 3T3/src cells with TMe1 cDNA, srcT1.1, T/1.2 and T/1.3, predominant expression of a 2.0 kb mRNA which codes for TM1 protein was detected. In addition, expression of the native 1.1 kb mRNA was also detectable. The vector-transduced control cell line, src/V, or the parental 3T3/src cells, did not express the 2.0 kb mRNA. The degree of expression of the endogenous 1.1 kb mRNA, in src/T1 cells as comparable to that found in the parental 3T3/ src cells and the vector control cells. Actin expression was also measured as a loading control.
Analysis of metabolically labeled proteins on 2-dimensional gels revealed that the v-src transformed NIH3T3 cells synthesized TM1 at about 50% levels (Cooper et al., 1985) , when compared to untransformed NIH3T3 cells. The src-T1 cells which were ]-methionine for 6 h and total proteins were analysed. The representative areas of the autoradiographs illustrating TM1 expression are shown. TM1 is identi®ed with an arrow. (c) The gels were scanned using an AMBIS radioanalytical imaging system and the amount of radioactivity in TM1 was calculated/ 10 6 c.p.m. of total radioactivity present on the gel (Prasad et al., 1993 (Prasad et al., , 1994 TM1-mediated tumor suppression GL Prasad et al generated by transduction of 3T3/src cells with TMe1 cDNA, elaborate up to 20-fold higher TM1 protein (Figure 1b and c) . This profound enhancement in the TM1 synthesis is due to the expression from the transduced cDNA sequence. TM1 protein was identi®ed by virtue of its mobility on 2D gels and its immunoreactivity to TM1 antisera.
V-SRC kinase activity
In order to establish that restoration of TM1 protein expression did not interfere with the expression and the enzymatic activity of v-src oncogene, a number of cell lines were tested for v-SRC tyrosine kinase activity (DeClue et al., 1993). As evident from Figure 2 , a high degree of the kinase activity was detected in TM1-expressing src/T1 cell lines, and the control src/v cell lines as well as the parental 3T3/src cell lines. But the kinase activity was either absent or marginally detectable in the normal NIH3T3 cells and in a rastransformed cell line of NIH3T3 cells (data not shown). Thus, gene transfer experiments did not, in any way alter the kinase activity of the transforming oncogene, v-src.
Morphology
Morphologically, the 3T3/src cells and src/V cells resembled very closely, and displayed multilayered growth with fusi form cells (Figure 3a) . The src/T1 cells, on the other hand had¯atter morphology with well spread out cytoplasm, thus resembling the normal NIH3T3 cells (not shown).
To visualize actin micro®laments and the association of TMs with the micro®laments, normal NIH3T3 and the other cell lines were stained with a polyclonal antiserum raised against TMs (Figure 3b) . These experiments were performed with the detergent (0.5% Triton X-100) extracted cells to visualize the cytoskeletal architecture of normal NIH3T3, 3T3/src and the revertants expressing TM1. This antibody recognizes both the high M r TMs as well as the low M r TM isoforms. In NIH3T3 cells extensive micro®lament structures were clearly visible, as evident from the TM staining. But in the transformed 3T3/src cells, although some micro®laments were visible, the micro®lament network is clearly disorganized compared with the NIH3T3 cells. Re-expression of TM1 (src/T1 cells) resulted in the re-organization of the micro®lament network leading to an improvement in the cytoarchitecture. In separate experiments, we have stained these cells with phalloidin to examine the factin; these results were similar to that of TM staining (data not shown). Thus, re-expression of a single isoform of TMs, restores`¯at' cell morphology, and improves micro®lamental organization in both ras-and src-transformed murine ®broblasts. These data point to the importance of TM1 in the maintenance of the integrity of actin-based cytoskeleton.
Growth properties
The growth properties of various cell lines, in monolayer, in presence of normal serum, were tested. All the src/T1 cell lines grew signi®cantly slowly than the parental, 3T3/src or src/V cells. The doubling time of various cell lines in monolayer NIH3T3, 19.6 h; 3T3/src is 18.73 h; src/v, 18.8 h; src/T1.1, 24.67 h; src/ T1.2, 25.3 h and src/T1.9, 32.4 h. Thus, elevated expression of TM1 in 3T3/src cells leads to decreased growth rates. This phenomenon is in contrast to the previous observation that increased expression of TM1 in ras-transformed murine ®broblasts did not consistently correlate with the growth rates. The in vitro kinase activity of v-SRC was assayed by immunoprecipitating 150 mg of total cellular proteins with a v-SRC speci®c antibody (Oncogene Science) as described by DeClue et al. (1993) . The immunoprecipitates were washed and incubated with [g-32 P]ATP for 20 min at 308C, washed and separated on SDS-polyacrylamide gels, transferred to a nitrocellulose membrane and autoradiographed Figure 3 (a) Morphology of 3T3/src, src/V and src/T1 cells: Cells grown in the monolayer under normal serum conditions were stained and photographed as described earlier (Braverman et al., 1996) . (b) Immuno¯uorescence microscopy of cells stained with anti-TM antiserum: The cells were cultured in chamber slides in monolayer, ®xed with 4% paraformaldehyde, extracted with 0.5% Triton X-100 and incubated with the antiserum (Prasad et al., 1993) . Then they were reacted with FITC-labeled anti-rabbit antibody (Molecular Probes) and mounted using Prolong antifade kit (Molecular Probes). The cells were viewed using a Zeiss confocal microscope at 12006 magni®cation TM1-mediated tumor suppression GL Prasad et al
The ability to grow in anchorage independent fashion is an important growth characteristic of the transformed cells. The parental 3T3/src and the vector transduced cells, src/v, grew rapidly and formed large colonies in soft agar, consistent with their transformed phenotype. Several src/T1 cell lines, on the other hand, failed to grow and form colonies in the agar under identical conditions. It should be noted that the src/T1 cells failed to grow in soft agar, even after prolonged culture (Figure 4) . This dramatic inhibition of anchorage independent growth by restoration of TM1 expression attests to anti-oncogenic properties of TM1. Tumor suppression by TM1 has been previously demonstrated in ras-transformed murine ®broblasts. Furthermore, antisense inhibition of TM1 expression is demonstrated to lead to acquisition of characteristics consistent with neoplastic phenotype (Boyd et al., 1995) . These data, taken together, support the hypothesis that the suppression of TM1 is a pivotal biochemical change in tumorigenesis by diverse oncogenic principles, and that TM1 is a suppressor of the transformed phenotype. Therefore, TM1 appears to belong to class II tumor suppressor proteins (Lee et al., 1991; Sers et al., 1997) . The class II suppressor proteins such as TM1 may themselves be targets of the class I tumor suppressors which include Rb and p53: mutations and/or deletions in the class I tumor suppressors result in the loss of function which ultimately culminates in the acquisition of the transformed phenotype.
Although restoration of TM1 expression clearly suppresses the transformed phenotype of ras and src, signi®cant dierences exist. Expression of enhanced TM1 in 3T3/src cells result in decreased growth rates of the src/T1 cell lines in monolayer. The doubling times are signi®cantly higher compared to those found with the transformed 3T3/src cells. But TM1 restoration does not aect the growth rates of DT cells. While the expression of a dierent tropomyosin, TM2, in DT cells is nearly abolished, it is still expressed in the srctransformed ®broblasts at about 25% levels found in NIH3T3 cells. Since TMs are known to form stable heterodimers in vivo (Lehrer and Staord, 1991; Jansco and Gracea, 1991) , it is unclear at present whether TM1 heterodimerizes with TM2 in src/T1 cells, and the eects of such associations on the cell physiology.
Like TM1, the DAN gene product (previously described as NO3) is also down regulated in several oncogne-transformed cells and suppresses the transformed phenotype of v-src (Ozaki and Sakiyama, 1993) . But it is not known whether DAN suppresses the transformed phenotype of other oncogenes. Similarly a number of ras-speci®c suppressors have been described previously (SchaÈ fer, 1994) . For example, Rsu-1 speci®cally blocks ras transformation (Cutler et al., 1992) . NIH3T3 cells expressing p33 rsu-1 have been shown to resist transformation by retroviruses containing v-ki-ras and v-Ha-ras genes, but were susceptible to v-src and v-mos containing viruses. Thus, it is a ras-speci®c suppressor. Other known ras suppressors inlcude the cytoskeletal proteins gelsolin (MuÈ llauer et al., 1993), a-actinin (GluÈ ck et al., 1993), and NF2 (Gusella et al., 1996) . The transformation sensitive H-rev-1 is shown to be a growth-inhibitory protein, which is expressed in normal and the revertant phenotype (Sers et al., 1997) . Like Hrev-1 expression, TM1 expression returns to the normal levels in the revertants of DT (Cooper et al., 1985) .
The mechanism of suppression of the transformed phenotype by TM1 is under investigation. It is known that src-mediated transformation is dependent upon endogenous Ras pathway (SchaÈ fer, 1994) . Src transformed ®broblasts have been shown to be reverted to normal phenotype by forced expression of either full length or truncated c-terminal portion of the rasspeci®c GTPase activating protein, p120 GAP (DeClue et al., 1993) . The revertants continued express pp60 src at the levels found in the parental transformed cells. Our data also indicate that in TM1 mediated reversion the endogenous kinase activity of the transforming oncogene is not altered, thus pointing to a downstream target(s). The expression of TM1 does not appear to be signi®cantly dierent in the v-src transformed NIH3T3 cells and those reverted by overexpression of p120 GAP (Prasad, unpublished data) . Earlier work from this laboratory indicated that in growth factor (TGFa and EGF) mediated signal oncogenic transformation, suppression of high M r TM expression precedes the disorganization of cytoskeletal architecture and malignant transformation of cells (Cooper et al., 1987) . Recent evidence points to a signal transduction pathway involving EGF which may regulate TM suppression and stress ®ber assembly, leading to oncogenic transformation (Masuda et al., 1996) . Furthermore, the involvement of Rho proteins which are known to regulate microfilament organization needs to be considered in TM1 mediated suppression of transformation and reorganization of the cytoskeleton. It is interesting to note that the p190, which is a GAP protein with a preference to Rho proteins, is involved in src signal Figure 4 Anchorage independent growth of src/T1 cells: Cells were seeded at 1000 cells/dish and cultured as described earlier (Braverman et al., 1996) . In the lower panel, representative light micrographs of 3T3/src and src/T1 cells are shown after culturing for 14 days. Colonies greater than 550 mm were counted and the quantitative data are shown in the upper panel (Prasad et al., 1993) transduction, and it is a suppressor of ras-transformed phenotype . In addition, interactions of TM1 with other TMs, as well as with other proteins such as caldesmon may prove to be important (Lin et al., 1997; Pittenger et al., 1994; Yamashiro et al., 1994) .
In summary, normal expression of TM1 protein is required for normal growth and dierentiation. A number of diverse primary oncogenic events suppress TM1, and hence a decrease in TM1 levels may be essential for facilitating neoplastic growth (Braverman et al., 1996) . The data presented in this communication, together with the ®ndings of our earlier work (Prasad et al., 1993; Braverman et al., 1996) demonstrate that TM1 is an anti-oncogene, and it belongs to class II tumor suppressor category. It appears that TM1 may be a general suppressor of transformation process, independent of the initial oncogenic events.
